GB2101599A - Derivatives of 4-pyrimidone - Google Patents

Abstract

The present invention provides compounds of formula (2):- <IMAGE> and their pharmaceutically acceptable salts which are useful as histamine H1- antagonists. In formula (2) R<1> is halogen or nitro; R<2> is C1-4 alkyl; R<3> is a C1-3 alkylene group; and R<4> is 3-pyridyl; N-oxo-3-pyridyl; 6-methyl-3-pyridyl; N-oxo- 6-methyl-3-pyridyl; 6-hydroxymethyl-3-pyridyl; 4,6-dimethyl-3-pyridyl; N-oxo- 4,6-dimethyl-3-pyridyl; 6-hydroxymethyl-4-methyl-3-pyridyl; 5,6-dimethyl-3- pyridyl; N-oxo-5,6-dimethyl-3-pyridyl; 6-hydroxymethyl-5-methyl-3-pyridyl; 4- pyridyl or N-oxo-4-pyridyl.

Description

SPECIFICATION Compounds This invention relates to certain pyrimidone derivatives, a process for their preparation, compositions containing them and their use as Histamine H,-antagonists.

Histamine, a physiologically active compound endogenous in mannals, exerts its action by interacting with certain sites called receptors. One type of receptor is known as a histamine H1-receptor (Ash and Schild, Brit. J. Pharmac. 1 966, 27, 427) and the actions of histamine at these receptors are inhibited by drugs commonly called "antihistamines" (histamine H,-antagonists) a common example of which is mepyramine. A second type of histamine receptor is known as the H2-receptor (Black et al Nature 1972, 236, 385). The actions of histamine at these receptors are not inhibited by mepyramine but are inhibited by burimamide. Compounds which inhibit the actions of histamine at histamine H2receptors are called histamine H2-antagonists.

US Patent No 4,154,834 discloses compounds of general formula (1):-

where Het is 2-or 4-imidazolyl optionally substituted by lower alkyl (preferably methyl), halogen (preferably chlorine or bromine), trifluoromethyl or hydroxymethyl; 2-pyridyl optionally substituted by one or two groups (which may be the same or different) selected from lower alkyl (preferably methyl), lower alkoxy (preferably methoxy), halogen (preferably chlorine or bromine), amino and hydroxy; 2 pyridyl with a phenyl, carbocyclic or cyclic ether ring containing 2 oxygen atoms fused to it; 2-thiazolyi; 3-isothiazolyl optionally substituted by chlorine or bromine; 3-(1 ,2,5)-thiadiazolyl optionally substituted by chlorine or bromine, or 2-(5-amino-1 ,3,4-thiadiazolyl); Y is sulphur or a methylene group; m is 1 or 2 and n is 2 or 3 such that their sum is 3 or 4 or when Y is methylene and Het is other than an imidazole ring, 2; Z is hydrogen or lower alkyl (preferably methyl); X is oxygen or sulphur; A is a straight or branched alkylene chain containing from 1-5 carbon atoms or (CH2)pW(CH2)q where W is oxygen or sulphur and p and q are such that their sum is from 1 to 4;Het' is a 5 or 6 membered heterocyclic ring selected from pyridine, pyridine-N-oxide, furan, thiophen, thiazole, oxazole, isothiazole, imidazole, pyrimidine, pyrazine, pyridazine or thiadiazole, which ring is optionally substituted by one or two (which may be the same or different) of the groups selected from lower alkyl, lower alkoxy, halo, hydroxy and amino, or Het' is a pyridine ring with a carbocyclic or cyclic ether ring containing two oxygen atoms fused to it, or Het' is a pyridine, imidazole or thiazole ring which has a benzene ring fused to it; and pharmaceutically acceptable salts thereof. These compounds are described as having combined histamine H, and H2-antagonist activity.

In particular US Patent No 4,154,834 discloses compounds of formula (1) where Het is 2-pyridyl having a substituent in position 3, Y is methylene and Het' is substituted pyridyl. It has now been found that when the 2-pyridyl group Het has a second substituent in position 5 the relative level of H, to H2 activity increases. A small number of compounds, which fall within the general class of compounds of formula (1), have now been found to be useful as histamine H,-antagonists, that is, for the treatment of diseases for example bronchial asthma, rhinitis, hayfever and allergic eczema whose symptoms are mediated through the action of histamine at H,-receptors.

Accordingly the present invention provides compounds of formula (2):-

and pharmaceutically acceptable salts thereof; where R1 is halogen or nitro; R2 is C14 alkyl; R3 is a C13 alkylene group; and R4 is 3-pyridyl; N-oxo-3-pyridyl; 6-methyl-3-pyridyl; N-oxo-6-methyl-3-pyridyl; 6hydroxymethyl-3-pyridyl; 4, 6-dimethyl-3-pyridyl; N-oxo-4,6-dimethyl-3-pyridyl; 6-hydroxymethyl-4methyl-3-pyridyl; 5,6-dim ethyl-3-pyridyl; N-oxo-5,6-dimethyl-3-pyridyl; 6-hydroxymethyl-5-methyl-3pyridyl; 4-pyridyl or N-oxo-4-pyridyl.

R' can represent any one of the halogens, fluorine, chlorine, bromine or iodine.

Preferably R' is bromine.

Examples of C14 alkyl groups for R2 are methyl, ethyl, n-propyl, iso-propyl, n-butyl and t-butyl.

Preferably R2 is methyl.

By way of example -R3- can be methylene, 1 ,2-ethanediyl, or 1,3-propanediyl.

Preferably R3 is 1,2-ethanediyl or 1,3-propanediyl.

Preferably the group R4 is an optionally substituted 3-pyridyl group. Preferably one substituent occupies position 6. Thus R4 is 6-methylpyrid-3-yl.

Examples of compounds within the scope of this invention are: 2-[4-(5-nitro-3-methylpyrid-2-yl)butylamino]-5-(6-methylpyrid-3-ylmethyl)-4-pyrimidone.

2-[4-(5-chloro-3-methylpyrid-2-yl)butylamino]-5-(6-methylpyrid-3-ylmethyl)-4-pyrimidone; 2-[4-( 5-iodo-3-methylpyrid-2-yl)buWlamino]-5-(6-methylpyrid-3-ylmethyl)-4-pyrimidone; 2-[4-(5-fluoro-3-methylpyrid-2-yl)butylamino]-5-(6-methylpyrid-3-ylmethyl)-4-pyrimidone; and their pharmaceutically acceptable salts.

Examples of compounds within the scope of this invention having the preferred R1 and R2 substituents are: 2-[4-(5-bromo-3-methylpyrid-2-yl)butylamino]-5-(6-methylpyrid-3-ylmethyl)-4-pyrimidone; 2-[4-(5-bromo-3-methylpyrid-2-yl)buWlaminoj-5-(pyrid-4-yl methyl)-4-pyrimidone; 2-[4-(5-bromo-3-methyl-pyrid-2-yl)butylamino]-5-(6-hydroxymethylpyrid-3-ylmethyl)-4- pyrimidone; and their pharmaceutically acceptable salts.

2-[4-( 5-Brnmo-3-methylpydd-2-yl)bulamino-5-( 6-methylpyrid-3-ylmethyl)-4-pyrimidone has been shown to have the particular advantage that unlike other histamine H1-antagonists it does not enter the central nervous system. This has been shown by rat whole body radiography.

The compounds of formula (2) are shown and described as 4-pyrimidones which exist in equilibrium with the corresponding 6-one tautomers. These compounds also exist to a lesser extent as the hydroxy tautomers, and the pyrimidine ring may also exist in the following tautomeric forms:

It will be understood that all these tautomeric forms are within the scope of the present invention.

The compounds of formula (2) form pharmaceutically acceptable salts with pharmaceutically acceptable salt-forming acids. Examples of these acids are hydrochloric, sulphuric, hydrobromic, phosphoric, tartaric, citric, ma leic, lactic, 2-hyd roxyetha nesu Iphonic, methanesulphonic, toluene-4sulphonic, ethanedisulphonic, ethanesulphonic and camphorsulphonic acids.

The compounds of this invention can be made by a process which comprises reacting a compound of formula (3):-

or a salt thereof, where R1, R2 and R3 are as defined with reference to formula (2) with a compound of formula (4):-

where R4 is as defined with reference to formula (2) and R6 is a group displaceable with amine, thereafter,where R4 is N-oxo-6-methyl-3-pyridyl; N-oxo-4,6-dimethyl-3-pyridyl; or N-oxo-5,6dimethyl-3-pyridyl; converting the compound of formula (2) so obtained into the corresponding compound of formula (2) where R4 is 6-hydroxymethyl-3-pyridyl; 6-hydroxymethyl-4-methyl-3-pyridyl; or 6-hydroxymethyl-5-methyl-3-pyridyl; and optionally converting the compound of formula (2) so obtained into a pharmaceutically acceptable salt.

The compounds of formula (2) where R4 is N-oxo-6-methyl-3-pyridyl; N-oxo-4,6-dimethyl-3pyridyl; or N-oxo-5,6-dimethyl-3-pyridyl can be converted into the corresponding compound of formula (2) where R4 is 6-hydroxymethyl-3-pyridyl; 6-hydroxymethyl-4-methyl-3-pyridyl; or 6-hydroxymethyl5-methyl-3-pyridyl; by reacting with an organic anhydride for example trifluoroacetic anhydride.

Pharmaceutically acceptable salts of compounds of formula (2) can be prepared by standard methods, for example by reacting a solution of the compound of formula (2) with a solution of the acid.

Examples of groups R6 are C1~4 alkylthio (particularly methylthio), benzylthio, chlorine, bromine and nitroamino. Preferably R6 is nitroamino.

The reaction can be carried out at an elevated temperature in the absence of a solvent, for example at from 800 to 1 700, preferably from 1200 to 1400, or in a solvent at an elevated temperature, for example at the reflux temperature of the reaction mixture. The choice of solvent is affected by solubility characteristics of the reactants and the nature of R6.Preferably the solvent is pyridine, a picoline or mixture of picolines, a C14 alkanol, preferably ethanol or 1-propanol, a C14 alkanol, 1,2-ethanediol, a ketone, for example acetone or 2-butanone, a high boiling alkoxyaryi ether for example anisole, or a polar aprotic solvent, for example dimethylformamide, dimethylacetamide, dimethylsulphoxide, hexamethylphosphoramide, sulpholane, acetonitrile or nitromethane.

Compounds of formula (3) can be prepared by carrying out a Sandmeyer reaction on the corresponding compound of formula (3a):-

that is by diazoatisation of the amino group R1 and displacing the diazo group with halo.

Compounds of formula (3) can also be prepared by halogenating the corresponding compound of formula (3b):-

where R2 and R3 are as defined with reference to formula (2) with halogen.

The preparation of amines of formula (3) where R' is in particular bromine is described in our copending U.K. Patent Application No. 8208749.

Thus a compound of formula (3c):-

and salts thereof where R2 and R3 are as defined with reference to formula (2) can be prepared by a process, which comprises reacting a compound of formula (3b):-

or a salt thereof, where R2 and R3 are as defined with reference to formula (2), with an electrophilic brominating agent.

Examples of electrophilic brominating agents are bromine or dibromocyanuric acid in a polar medium which generates Br+. Examples of such media are oleum and fluorosulphonic acid. Br+ can also be generated from hydrobromic acid and bromide ion in oxidizing or oxidizing polar media. For example hydrobromic acid is oxidized by solutions of sulphur trioxide to bromine which dissociates giving Br+. The sulphur trioxide solution can be in a freon for example 1,1 ,2-trifluorotrichloroethane or in sulphuric acid i.e. oleum. The hydrobromic acid can be derived from the dihydrobromide salt of the compound of formula (3b), particularly when the reaction is carried out using sulphur trioxide and freon.Where the sulphur trioxide solution is oleum, the hydrobromic acid can be generated from a bromide salt for example an alkali metal salt in particular potassium bromide.

Compounds of formula (3b) form neutral complexes with sulphur trioxide. The effect of this is that the pyridine ring in the compounds of formula (3b) is activated to bromination. Thus preferably the medium is one which dissolves sulphur trioxide.

Two preferable media for carrying out the bromination reactions are oleum and sulphur trioxide in Freon (RTM). Where the medium is oleum, in practice it is at least 20% w/w. Preferably it is at least 65% w/w. The more concentrated the oleum, the lower is the temperature at which the reaction can be carried out. For example where the medium is 20% oleum the reaction requires elevated temperatures to proceed in a short period and at this concentration of oleum it is carried out at 1 000C and above.

Where the medium is 65% oleum the reaction can be carried at from OOC to 1 O00C, preferably from 50-600C especially 55--580C.

Where the medium is sulphur trioxide in freon the reaction is carried out at from ambient temperature to the reflux temperature of the solvent.

Compounds of formula (3) and (3a) can also be prepared by reducing a corresponding cyano compound of formula (5):-

where R7 is halogen, nitro or amino and R2 and R3 are as defined with reference to formula (2) with a reducing agent which reduces cyano to amino without reducing the group R7 in a reaction medium which is inert to the reagents and product. For example the reducing agent can be lithium aluminium hydride or diborane. The reaction medium can be a dialkyl ether for example diethyl ether or a cyclic ether for example tetrahydrofuran or dioxan. Where the reducing agent is lithium aluminium hydride or diborane it will be appreciated that the reaction medium is anhydrous.

Compounds of formula (5) where R7 is amino can also be prepared by reducing the corresponding nitro-compound of formula (5) where R7 is nitro. The reduction can be carried out by hydrogenation.

Compounds of formula (5) can be prepared by reacting a disubstituted chloropyridine of formula (6):-

where R2 is as defined with reference to formula (2) and R7 is halogen, nitro or amino; with a malonic acid ester of formula (7):-

where R3 is as previously defined and R is an ester forming group, in the presence of a strong base in an inert reaction medium, and therafter de-esterifying and decarboxylating the product.

In particular the groups R can be ethyl.

In particular the strong base can be sodium hydride.

The reaction medium is one which is substantially inert to the reagents and product. In particular the medium can be dry tetrahydrofuran.

Compounds of formula (3b) can also be prepared by reacting an alkali metal derivative of a compound of formula (8):-

where R2 is as defined with reference to formula (2) with a compound of formula (9):- XR3NH2 (9) or a salt thereof where X is halogen and R3 is as defined with reference to formula (2).

In the compound of formula (9), X can be chlorine, bromine or iodine. In particular it is chlorine.

The alkali metal derivative can be a lithium, sodium or potassium derivative. In particular it is the sodium derivative.

The alkali metal derivative of compound of formula (8) can be prepared in situ by reacting the compound of formula (8), with an alkali metal amide (in particular sodamide, where the alkali metal is sodium) in which case the solvent is preferably liquid ammonia or an alkyl alkali metal (in particular butyl lithium, where the alkali metal is lithium) in which case the solvent is preferably an ether, for example diethylether or tetrahydrofuran.

This reaction is carried out at reduced temperatures. For example where the reaction is carried out in liquid ammonia, the temperature is at or below the boiling point of ammonia and where a derivative of formula (8) is generated in situ from an alkyl alkali metal the reaction is carried out at liquid nitrogen temperature, preferably in an inert atmosphere.

The compounds of formula (8) and (9) are known or can be made by known methods.

The compounds of formula (4):-

are known or can be made by analogy with known processes as disclosed in for example US Patent No 4,154,834 and European Patent Specification No 17,679.

Compounds of formula (2) can also be prepared by reacting a guanidine of formula (10):-

where R', R2 and R3 are as defined with reference to formula (2) with a compound of formula (11):-

where R4 is as defined with reference to formula (4) and R8 is C14 alkyl (particularly ethyl) benzyl or phenyl.

The reaction can be carried out by heating the guanidine of formula (10) with the compound of formula (11) optionally in a solvent for example an alcohol corresponding to the ester function in the compound of formula (11) that is RBOH, at an elevated temperature, preferably in the presence of a base in particular the sodium alkoxide NaOR8 corresponding to the ester function of the compound of formula (11).

The guanidines of formula (10) can be prepared by reacting an amine of formula (3) with a compound of formula (12):-

where R9 is a leaving group for example methylthio or 3,5-dimethylpyrazolyl.

The histamine H1-antagonist activity of the compounds of formula (2) can be demonstrated in vitro in the guinea pig ileum test. In this test an isolated portion of the guinea pig ileum is secured under tension (500 mg) between an anchorage and a transducer in a 10 ml tissue bath and immersed in magnesium free Tyrode solution with constant aeration at a temperature of 300 C. The output from the transducer is amplified. The amplified output is in turn fed to a flat bed recorder. Measured amounts of histamine are added to the tissue bath so that the histamine concentration increases stepwise until the force of the contraction reaches a maximum. The tissue bath is washed out and filled with fresh magnesium free Tyrode solution containing compound under test.The solution is left in contact with the tissue for 8 min. and measured amounts of histamine are added again until a maximum contraction is recorded. The assay is repeated with increasing concentrations of test compound and the dose of histamine giving 50% of maximum contraction is noted. A dose ratio (DR) was calculated by comparing the concentrations of histamine required to produce 50% maximum response in the absence and in the presence of the antagonist. A plot of Log DR-1 against LOG D (the concentration of compound under test) is made and the point of intersection with the Log (DR-1) ordinate is taken as the measure of the activity (pea2 value). The compounds of Examples 1 to 12 have pA2 values greater than 8.

The histamine H2-antagonist activity of the compounds of formula (I) can be demonstrated in vitro in the guinea pig atrium test. In this test a spontaneously beating isolated portion of the guinea pig right atrium is secured under tension (300 mg) between an anchorage and a transducer in a 1 5 ml tissue bath and immersed in McEwens solution with constant aeration at a temperature of 370C. The output from the transducer is amplified. Output is in turn fed to a flat bed recorder. Measured amounts of histamine are added to the tissue bath so that the histamine concentration increases step-wise until the rate of beating reaches a maximum. The tissue bath is washed out and filled with fresh McEwens solution containing compound under test.The solution is left in contact with the tissue for 60 min. and measured amounts of histamine are added again until a maximum rate is recorded. The assay is repeated with increasing concentrations of test compound and the dose of histamine giving 50% of maximum rate is noted. A dose ratio (DR) was calculated by comparing the concentrations of histamine required to produce 50% maximum response in the absence and in the presence of the antagonist. A plot of Log DR-1 against LOG D (the concentration of compound under test) is made and the point of intersection with the Log (DR-1) ordinate is taken as the measure of the activity (pA2 value). The compounds of Examples 1 to 12 have pA2 values of less than 7.5.

The activity of compounds of formula (2) as histamine H,-antagonists can be demonstrated in vivo by the inhibition of histamine induced bronchoconstriction. Guinea pigs of either sex are anaesthetised by intraperitoneal injection of sodium pentobarbitone, 90 mg/kg. The trachea is cannulated. The animal is respired artificially with a fixed volume of air just adequate to inflate the lungs. The pressure needed to inflate the lungs is monitored from the respiratory system using a low pressure transducer. Intravenous injection of histamine causes dose-dependent increases in the pressure to inflate the lungs reflecting the bronchoconstrictor action of histamine. Responses to histamine can be antagonised using histamine H,-receptor antagonists.

Dose-response curves to histamine are established at 20, 40, 80, 160 and 320 nmols/kg.

Antagonists are then adminstered by intravenous injection and 5 minutes later a new histamine doseresponse curve is established increasing the doses of histamine as necessary. The effect of the antagonist can be quantified by the displacement, to the right, of the histamine dose-response curve, expressed as a dose-ratio. A series of doses of antagonists may be given to each animal allowing calculation of dose-ratios for each dose of antagonist. The compounds of the Examples hereafter cause displacement of histamine dose-response curves with a dose-ratio of 10 at doses of less than 0.8 micromole kg-' i.v.

The activity of the compounds of formula (2) as histamine H2-antagonists can be demonstrated in vivo by the inhibition of histamine-stimulated secretion of gastric acid from the lumen-perfused stomachs of rats anaesthetised with urethane. This procedure is referred to in Ash and Schild, Brit. J.

Pharmac. Chemother., 27, 247 (1966). The compounds of the Examples hereafter cause 50% inhibition of maximal acid secretion at doses of 0.1 to 30 micromole kg-l i.v.

In order to use the compounds of the invention as histamine H,-antagonists, they can be formulated as pharmaceutical compositions in accordance with standard pharmaceutical procedure.

The invention also includes pharmaceutical compositions comprising a compound of formula (2) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

Compounds of formula (2) and their pharmaceutically acceptable salts can be administered topically or systemically.

Topical formulations for administration to the skin include lotions and creams. Topical formulations for administration to the respiratory tract include solutions for application via a nebulizer or as an aerosol, or a microfine insufflatable powder. The active ingredient in an insufflatable powder has a small particle size i.e. less than 50 microns and preferably less than 10 microns. The active material is co-presented with a solid carrier for example lactose which has a particle size of less than 50 microns.

Systemic administration can be achieved by rectal, oral or parenteral administration. A typical suppository formulation comprises the active compound with a binding agent and/or lubricating agent for example gelatine or cocoa butter or other low melting vegetable waxes or fats. Typical parenteral compositions consist of a solution or suspension of the active material in a sterile aqueous carrier of parenterally acceptable oil.

Compounds of formula (2) which are active when given orally can be formulated as syrups, tablets, capsules and lozenges. A syrup formulation generally consists of a suspension or solution of the compound in a liquid carrier for example ethanol, glycerine or water with a flavouring or colouring agent. Where the composition is in the form of a capsule, the solid in granular form optionally with a binding agent is encased in a gelatin shell. Where the composition is in the form of a tablet, any suitable pharmaceutical carrier routinely used for preparing solid formulations can be used. Examples of such carriers include magnesium stearate, starch, lactose, glucose, sucrose, and cellulose. Preferably the composition is in unit dose form for example a tablet, capsule or metered aerosol so that the patient may administer to himself a single dose.

Where appropriate. small amounts of bronchodilators and anti-asthmatics for example sympathomimetic amines particularly isoprenaline, isoetharine, salbutamol, phenylephrine and ephedrine; xanthine derivatives particularly theophylline and aminophylline; and corticosteroids particularly prednisolone and adrenal stimulants particularly ACTH can be included. As in common practice, the compositions will usually be accompanied by written or printed directions for use in the medical treatment concerned, in this case as a histamine H,-antagonists for treatment of, for example, asthma, hayfever rhinitis or allergic eczema.

Each dosage unit for oral administration contains preferably from 1 to 200 mg of a compound of formula (2) or a pharmaceutically acceptable salt thereof calculated as the free base.

The pharmaceutical compositions of the invention will normally be administered to a man for the treatment of rhinitis, hayfever, bronchial asthma or allergic eczema. An adult patient will receive an oral dose of between 1 5 mg and 400 mg and preferably between 15 mg and 200 mg or an intravenous, subcutaneous or intramuscular dose of between 1 mg and 50 mg, and preferably between 1 mg and 10 mg of compound of formula (I) or pharmaceutically acceptable salt thereof calculated as the free base, the composition being administered 1 to 4 times per day.

The following Examples illustrate the invention.

Examples Example 1 (a) 2-(2-Cyanoethyl)malonic acid diethyl ester (148.3 g) was reacted with sodium hydride (15.3 g) in tetrahydrofuran at 200C. 2-Chloro-3-methyl-5-nitro-pyridine (100 g) was added and the internal temperature was raised to 1 000C (some tetrahydrofuran was distilled off) over 14 hrs. The reaction mixture was partitioned between water and chloroform, the chloroform extract was dried, treated with charcoal and filtered through a silica bed and then evaporated to dryness. Crystallisation of the residue from ethanol gave 4-(3-methyl-5-nitropyrid-2-yl)-4,4-bis(carbethoxy)-butyronitrile (99 9). m.p. 64- 65.50C.

(b) 4-(3-Methyl-5-nitropyrid-2-yl)-4,4-bis(carbethoxy)-butyronitrile (99 g) was stirred in a mixture of ethanol (1200 ml) and sodium hydroxide solution (1130 ml, molar) for 1 6 hours. The pH was lowered to 2 by the addition of hydrochloric acid, and the ethanol was distillled off. The product was extracted with chloroform to leave an oil (57.1 9). This oil was extracted with dilute hydrochloric acid (554 ml; 1.5N), re-extracted with more dilute hydrochloric acid and the combined acid extracts were treated with charcoal, filtered and then extracted with chloroform, to give 5-nitro-2-(3cyanopropyl)-3-methyl-pyridine (49.5 g) m.p. 51.5--530C.

(c) 5-Nitro-2-(3-cyanopropyl)-3-methylpyridine (5.9 g) was hydrogenated in ethanol (150 ml) with palladium on charcoal (0.59 g of 10%) at 140 kPa, for 2.5 hrs. The filtered solution was concentrated to dryness, the residue was triturated with ether to give 5-amino-2-(3-cyanopropyl)-3methylpyridine (4.70 g) m.p. 103-1 OS0 C.

(d) 5-Amino-2-(3-cyanopropyl)-3-methylpyridine (23.0 g) was reduced with lithium aluminium hydride (12.47 g) in a mixture of tetrahydrofuran (750 ml) and diethylether (750 ml) over 3 hours, to give 5-amino-2-(4-aminobutyl)-3-methylpyridine (20.8 g) as an amber oil.N.M.R. (CDCl3):- assignment, 8 (p.p.m.) multiplicity; -CH2 CH2 CH2NH2, 1.3-1.9, m; 3-CH3, 2.22, s; CH2 (CH2)2CH2NH2, 2.6-2.8, m; S-NH2, ca 3.5, broad resonance; 4-pyridyl proton, 6.77, d; 6-pyridyl proton, 7.88, d; (e) 5-Amino-2-(4-aminobutyl)-3-methylpyridine (5.11 g) in hydrobromic acid (48%, 47 ml) was reacted with cuprous bromide (4.98 g) and copper bronze (0.18 g). A solution of sodium nitrite (2.45 g) in water (16 ml) was added at 5 to 8 C over 45 minutes, the reaction mixture was allowed to stir at 5 to 80C for a further hour and then stirred at room temperature for 3.5 hours.The reaction mixture was diluted with water, and hydrogen sulphide gas was passed, while the pH was progressively raised to 11 by the addition of sodium hydroxide solution. The precipitated copper salts were filtered off at intervals during the above procedure. The product was then extracted at pH 11 with chloroform to give 5bromo-2-(4-aminobutyl)-3-methylpyridine (4.95 g) m.p. 35-37 0C (f) 5-Bromo-2-(4-aminobutyl)-3-methylpyridine (2.12 g) and 2-nitroamino-5-(6-methylpyrid-3ylmethyl)-4-pyrimidone (3.18 g) were refluxed in pyridine (12 ml) for 9.5 hrs. The pyridine was removed in vacuo and the residue was re-evaporated with n-propanol (2x50 ml), triturated with chloroform, filtered and the solution was chromatographed on silica in chloroform-methanol (10:1).

The product was crystallised from ethanol-ether to give 2-[4-(5-bromo-3-methylpyrid-2-yl)- butylamino]-5-(6-methylpyrid-3-ylmethyl)-4-pyrimidone (2.44 g) m.p. 151--1520C.

C21 H24BrNsO Requires C, 57.01; H, 5.46; N, 15.83; Br, 18.06; Found C, 56.83; H, 5.30; N, 15.69; bur,18.11; Example 2 Reacting 5-bromo-2-(4-aminobutyl)-3-methylpyridine, the product from Example 1 (e) (0.5 g), with 2-methylthio-5-(pyrid-4-ylmethyl)-4-pyrimidone (0.57 gm) under conditions analogous to those described in Example 1 (f) gave 2-[4-(5-bromo-3-methylpyrid-2-yl)-butylamino]-5-(pyrid-4-ylmethyl)- pyrimidone (0.15 gm) m.p. 1760--177.50C.

C20H22BrN50 Requires C, 56.08; H, 5.17; N, 16.35 Br, 18.65; Found C, 56.18; H, 5.08; N, 16.45; Br, 18.43; Example 3 Reacting S-bromo-2-(4-aminobutyl)-3-methylpyridine, the product from Example 1 (e) (1.04 g), with 2-nitroamino-5-(N-oxo-6-methylpyrid-3-ylmethyl)-4-pyrimidone (1.42 g) under conditions analogous to those described in Example 1 (f) gave 2-[4-(5-bromo-3-methylpyrid-2-yl)-butylamino]-5- (N-oxo-6-methylpyrid-3-ylmethyl)-4-pyrimidone (0.48 g) m.p. 1930--194.50C.

C21 H24BrN5O2 Requires C, 55.03; H, 5.28; N, 1 5.28; Br, 17.43; Found C, 54.67; H, 5.41; N, 1 5.09; Br, 17.60; Example 4 2-[4-(5-Bromo-3-methylpyrid-2-yl)butyla mino]-S-(N-oxo-6-methylpyrid-3-ylmethyl)-4- pyrimidone (the product of Example 3) (0.9 g) was reacted with trifluoroacetic anhydride (1.65 g) in dichloromethane (6 ml) for two days, followed by removal of the solvent in vacuo, dissolution of the residue in chloroform, washing of the chloroform solution with 1 0% sodium bicarbonate solution, and concentrating the chloroform solution to dryness gave 2-[4-(5-bromo-3-methylpyrid-2-yl)- butylamino]-5-(6-hydroxymethylpyrid-3-yl-methyl)-4-pyrimidone (0.42 g), m.p. 61--700CC- resolidifying ca 1200 C, remelts 160--1650C.

C2,H24BrNsO2, 1 .23H2O Requires C, 52.50; H, 5.50; N, 14.58; Found C, 52.34; H, 5.35; N, 14.49; (Weight loss 40-800C, 4.6%=1 .23 H2O) Example 5 (a) Reaction of 5-amino-2-(4-aminobutyl)-3-methylpyridine (the product of Example 1 (d)) (1.5 g), with sodium nitrite, cuprous chloride, copper bronze and hydrochloric acid under conditions analogous to those of Example 1 (e) gave 5-chloro-2-(4-aminobutyl)-3-methylpyridine (1.0 g) m.p. 118-1 200C.

(b) Reaction of 5-chloro-2-(4-aminobutyl)-3-methylpyridine [from Example 5(a)] (1.0 g) with 2nitroamino-5-(6-methylpyrid-3-ylmethyl)-4-pyrimidone (1.23 g) under conditions analogous to those described in Example 1 (f) gave 2-[4-( 5-chloro-3-methylpyrid-2-yl)butylamino]-5-(6-methylpyrid-3- ylmethyl)-4-pyrimidone (0.53 g) m.p. 140--1410C.

C21H24ClN5O Requires C, 63.39; H, 6.08; N, 17.60; Cl, 8.91; Found C, 63.18; H, 6.22; N, 17.42; Cl, 9.18; Example 6 (a) 5-Nitro-3-methyl-2-cyanopropylpyridine (2 g) in tetrahydrofuran (20 ml) was reduced with diborane (0.045 mole) in tetrahydrofuran (45 ml) over 2 hours 20 minutes. The reaction mixture was added slowly to ethanol (100 ml), stirred for 1 hour, acidifed with hydrochloric acid (100 ml, molar), stirred for 20 minutes and concentrated to low volume.The solution was washed with chloroform, basified with sodium hydroxide to pH 12 and extracted with chloroform to give 3-methyl-5-nitro-2-(4aminobutyl)pyridine, as an oil (0.9 g) N.M.R. (CDCl3) assignment, 8 (p.p.m.), multiplicity; (CH2)2CH2NH2, 1.4-1.9, m; NH2, 1.98, broad s; 3-CH3 2.48, s, CH2(CH2)2CH2NH2, m; 4H m; 4--Hpyridyl,8.21, d; 6-H pyridyl, 9.19, d.

(b) The product from Example 6(a) (0.85 g) was heated under reflux in pyridine (5 ml) with 2nitroamino-5-(6-methylpyrid-3-ylmethyl)-4-pyrimidone (1.25 g) under nitrogen, for 6 hours. The pyridine was removed in vacuo and the residue was chromatographed on silica in chloroform-methanol to give 2-[4-( 5-nitro-3-methylpyrid-2-yl)butylaminoj-S-(6-methylpyrid-3-ylmethyl)-4-pyrimidone (0.345 g) m.p. 141-1420C.

C21 H24NsO3 Requires C, 61.75; H, 5.92; N, 20.58; Found C, 61.20; H, 5.92; N, 20.48; Example 7 (a) 5-Amino-2-[4-aminobutyl]-3-methylpyridine (2.17 g) in 20% sulphuric acid (25 ml) at -50C was reacted with a solution of sodium nitrite (1 g) in water (5 ml) over 20 minutes. After a further 1 5 minutes at -90C the reaction mixture was added to a mixture of potassium iodide (4 g) and cuprous iodide (0.5 g) in water (65 ml) at 1 00C and then stirred at room temperature for 30 minutes. Saturated sodium thiosulphate solution (10 ml) was added and the pH was brought to 12 with sodium hydroxide.

Chloroform extraction of the reaction mixture gave 5-iodo-3-methyl-2-(4-aminobutyl)pyridine as a dark oil (2.45 g). N.M.R. (CDCl3) assignment, 8 (p.p.m.), multiplicity; (CH2)2CH2NH2, 1.4-2.0, m; NH2, 1.69, s; 3-CH3, 2.28, s; CH2(CH2)2CH2NH2, 2.76, m; 4-H pyridyl, 7.75, m; 6-H pyridyl, 8.57, m; (b) The product of Example 7(a) (0.6 g) and 2-nitroamino-5-(6-methylpyrid-3-ylmethyl(-4pyrimidone (0.6 g) were heated in pyridine (3 ml) for 5 hours.After removal of the pyridine in vacuo the residue was chromatographed in chloroform-methanol on silica to give 2-[4-(5-iodo-3-methylpyrid-2- yl)butylamino]-5-(6-methylpyrid-3-ylmethyl)-4-pyrimidone m.p. 1 60-1 61.50 C.

Example 8 (a) A cooled (00 C) mixture of 5-amino-2-[4-aminobutyl]-3-methylpyridine (0.86 g) and fluoroboric acid (5 ml) in ethanol (30 ml) was reacted with amyl nitrite (3 ml) over 15 minutes and then stirred for a further 1 5 minutes, diluted with diethyl ether at OOC to give 5-diazo-2-(4-aminobutyl)-3 methylpyridine fluoroborate (1.88 g) m.p. 80-1 200 C (dec).

This salt (1.78 g) was added portionwise to petroleum ether (75 ml) stirred at 95-1 000C to give an oil which solidified on cooling. The petroleum ether was decanted and the solid was partitioned between water and chloroform. The pH of the aqueous portion was raised to 1 3 with sodium hydroxide and the product was extracted with chloroform to give 5-fluoro-2-(4-aminobutyl)-3-methylpyridine (0.69 g) as an amber oil.

N.M.R. (CDCl3) assignment 8 (p.p.m.) multiplicity; NH2 1.39, broad s; CH2CH2CH2CH2NH2, 1.4- 1.9, m; 3--CH,, 2.3, s; CH2(CH2)CH2NH2, 2.6-2.8, m; 4-H pyridyl, 7.14, d of d; 6-H pyridyl, 8.19, d; (b) The product from Example 8(a) (0.60 g) was refluxed in pyridine (3 ml) with 2-nitroamino-5 (6-methylpyrid-3-yl-methyl)-4-pyrimidone (0.86 g) for 7 hours to give, after concentration, chromatography in chloroform-methanol, and crystallisation from acetonitrile, 2-[4-(5-fluoro-3- methylpyridyl-2-yl)butylamino]-5-(6-methylpyrid-3-ylmethyl)-4-pyrimidone, (1.04 g) m.p. 131.5 133.5"C.

C21H24FN5O Requires C, 66.16; H, 6.35; N, 18.37; Found C, 66.25; H, 6.36; N, 18.13; Example 9 The product from Example 1 (e) (2.1 gm) and 2-nitroamino-5-(5,6-dimethyl-N-oxo-pyrid-3- ylmethyl)-4-pyrimidone (2.51 gm) were refluxed in pyridine (6 ml) for 13.5 hrs. The pyridine was removed in vacuo, and the last traces of pyridine were removed by azeotroping with n-propanol. The residue was then dissolved in hot ethanol (50 ml) and any undissolved solid filtered off. The filtrate was concentrated while hot to 20 ml volume and on cooling white crystals deposited. These were recrystallised from ethanol and dimethylformamide to give 2-[4-(5-bromo-3-methylpyrid-2 yl)butylamino]-5-(5,6-dimethylpyrid-N-oxo-3-ylmethyl)-4-pyrimidone (2.5 gm) m.p. 2040--2060C.

C22H26BrN502 Requires C, 55.81 H, 5.60 N, 1 5.00 Br, 17.23; Found C, 55.93 H, 5.54 N, 14.82 Br, 16.92; Example 10 The product from Example 1 (e) (1.06 gm) and 2-nitro-amino-5-(N-oxo-pyrid-4-ylmethyl)-4- pyrimidone (1.14 gm) were refluxed in anisole (4 ml) for 7.5 hrs. The anisole was removed in vacuo.

The residue obtained was chromatographed on silica in chloroform-methanol (4:1). The product was crystallised from acetonitrile-water (9:1) to give 2-[4-( 5-bromo-3-methylpyridyl-2-yl)-butylamino]-S- (N-oxo-pyrid- 4-ylmethyl)-4-pyrimidone (0.40 gm) m.p. 1100--1150C.

C2OH22BrN5o2 Requires C 54.06 H 4.99 N 15.76 Br 17.98 C2OH22BrN502.0 62H20 Requires C 52.70 H 5.14 N 15.37 Br 17.54 Found C 52.68 H 4.92 N 15.45 Br 18.26 Example 11 A mixture of 5-bromo-2-(4-aminobutyl)-3-methylpyridine, (0.68 g) and 2-nitroamino-5-(4,6 dimethyl-3-pyridylmethyl)-4-pyrimidone (0.83 g) in anisole (25 ml) were refluxed for 4 hrs. Petroieum ether was added to precipitate the product which was then chromatographed on a silica gel column eluting with chloroform. The product was crystallised from ethyl acetate to give 2-[4-(5-bromo-3 methylpyrid-2-yl)-butylamino]-5-(4,6-dimethyl-3-pyridylmethyl)-4-pyrimidone (0.77 g) m.p. 110- 121 C.

C22H26N5BrOl 1.27 H2O Requires C. 55.00; H. 6.01; N. 14.58; Br. 1 6.63 Found C. 54.87; H. 5.93; N. 14.38; Br. 16.33 (Wt loss 40-11 00C=1 .33 H2O).

Example 12 A mixture of 5-bromo-2-(4-aminobutyl)-3-methylpyridine, (0.68 g) and 2-nitroamino-5-(5,6dimethyl-3-pyridylmethyl)-4-pyrimidone (0.83 g) in anisole (25 ml) were refluxed for 4 hrs. Excess petroleum ether was added to precipitate the product which was then chromatographed on a silica gel column in CHCl3. The product crystallised under ether to give 2-[4-(5-bromo-3-methyl-pyrid-2-yl)- butylamino]-5-(5,6-dimethyl-3-pyridylmethyl)-4-pyrimidone (0.6 g) m.p. 126--80C.

C22H2eN5BrO 0.6 H2O Requires C. 56.45; H. 5.87; N. 14.96; Br. 17.07 Found C. 56.44; H. 5.68; N. 14.82; Br. 1 6.96 Example 13 Trifluoroacetic anhydride (1.9 ml) was mixed with a suspension of the product from Example 8 (1.6 gm), in dry dichloromethane (10 ml) and the mixture was allowed to stand for two days. The solvent was removed in vacuo, and the residue was dissolved in chloroform. The chloroform solution was washed with 10% sodium bicarbonate solution. Evaporation of the chloroform gave a solid (1.7 gm) which was crystallised from ethanol (10 ml) and adding water (20 ml).Solid obtained was recrystallised from acetonitrile-water (9:1) to give 2-[4-(5-bromo-3-methylpyrid-2-yl)-butylamino-]-5- (5-methyl-6-hydroxymethylpyrid-3-ylmethyl)-4-pyrimidone (0.99 gm) m.p. 1360--1410C.

C22H25BrN502 Requires C 55.93 H 5.54 N 14.82 Br 16.92 C22H26BrN502.2.0.H20 Requires C 51.97 H 5.95 N 13.78 Br 15.72 Found C 51.82 H 5.89 N 13.83 Br 15.48 Example 14 A solution of 1 2-ethanedisulphonic acid (15.3 g) in methanol (48 ml) was added to a solution of 2-[4-( 5-bromo-3-methylpyrid-2-yl)-butylaminoj-S-(6-methyl-pyrid-3-ylmethyl)-4-pyrimidone (20 g) in methanol (68 ml). A solid crystallised on cooling which was removed by filtration, washed with cold methanol and dried to yield the neutral ethanesulphonate salt of 2-[4-(5-bromo-3-methylpyrid-2-yl) butylamino]-5-(6-methyl-pyrid-3-ylmethyl)-4-pyrimidone (31 g) m.p. 182--50C.

C2XH24N50Br. 1 .5C2H6o6S22H2o Requires C, 37.75; H, 4.88; N, 9.17; S, 12.60; Br, 10.46 Found C, 37.60; H, 4.78; N, 9.10; S, 12.30; Br, 10.71 Example 15 A pharmaceutical composition for oral administration is prepared containing

% by weight 2-[4-(S-bromo-3-methylpydd-2-yl)-buWlamino]S(6methylpynd A l 3-yl-methyl)-4-pyrimidone 55 Dibasic calcium phosphate dihydrate 20 Approved coloring agent 0.5 Polyvinylpyrrolidone 4.0 Microcrystalline Cellulose 8.0 B Maize Starch 8.0 Sodium glycollate 4.0 Magnesium Stearate 0.5 by mixing together the ingredients A (substituting lactose or microcrystalline cellose for dibasic calcium phosphate dihydrate if desired), adding a concentrated solution of polyvinylpyrrolidone and granulating, dying and screening the dried granules; adding the ingredients B to the dried granules and compressing the mixture into tablets containing 5 mg, 25 mg or 50 mg of the free base.

Example 16 A pharmaceutical composition for injectable administration is prepared by forming a solution of 2-[4-( S-bromo-3-methyl-pyrid-2-yl)-buWlaminoj5(6methylpydd3ylmethyl)4pyrimidone hydrochloride salt in sterile water to give a 1 to 5% w/w solution. The solution is clarified by filtration and filled into vials which are sealed and sterilised. A suitable vial contains 2 ml of the solution.

Claims (12)

Claims

1. A compound of

and pharmaceutically acceptable salts thereof; where R1 is halogen or nitro; R2 is C14 alkyl; R3 is a C13 al kylene group; and R4 is 3-pyridyl; N-oxo-3-pyridyl; 6-methyl-3-pyridyl; N-oxo-6-methyl-3-pyridyl; 6hydroxymethyl-3-pyridyl; 4,6-dimethyl-3-pyridyl; N-oxo-4,6-dimethyl-3-pyridyl; 6-hydroxymethyl-4methyl-3-pyridyl; S,6-dimethyl-3-pyridyl; N-oxo-5,6-dimethyl-3-pyridyl; 6-hydroxymethyl-5-methyl-3pyridyl; 4-pyridyl or N-oxo-4-pyridyl.

2. A compound as claimed in claim 1, wherein R1 is bromine.

3. A compound as claimed in claim 1 or claim 2, where R2 is methyl.

4. A compound as claimed in any one of claims 1 to 3, where R4 is pyrid-3-yl, 6-methyl-pyrid-3- yl, 6-hydroxymethyl-pyrid-3-yl or 5,6-dimethyl-6-pyrid-3-yl.

5. 2-[4-(S-Bromo-3-methylpyrid-2-yl)butylamino]-S-(6-methylpyrid-3-ylmethyl)-4-pyrimidone and pharmaceutically acceptable salts thereof.

6.2-[4-(5-Bromo-3-methylpyrid-2-yl)butylamino]-5-(pyrid-4-yl and pharmaceutically acceptable salts thereof.

7.2-[4-(5-Bromo-3-methyl-pyrid-2-yl)butylamino]-5-(6-hydroxymethylpyrid-3-ylmethyl)-4- pyrimidone and pharmaceutically acceptable salts thereof.

8. A hydrochloride salt of a compound of formula (2) claimed in any one of claims 1 to 7.

9. A process for preparing a compound as claimed in any one of claims 1 to 8 which comprises reacting a compound of formula (3):-

or a salt thereof, where R', R2 and R3 are as defined with reference to formula (2) with a compound of formula (4):-

where R4 is as defined with reference to formula (2) and R6 is a group displaceable with amine, thereafter where R4 is N-oxo-6-methyl-3-pyridyl; N-oxo-4,6-dimethyl-3-pyridyl; or N-oxo-5,6- dimethyl-3-pyridyl; converting the compound of formula (2) so obtained into the corresponding compound of formula (2) where R4 is 6-hydroxymethyl-3-pyridyl; 6-hydroxymethyl-4-methyl-3-pyridyl; or 6-hydroxymethyl-5-methyl-3-pyridyl; and optionally converting the compound of formula (2) so obtained into a pharmaceutically acceptable salt.

or by reacting a guanidine of formula (10):-

where R1, R2 and R3 are as defined with reference to formula (2) with a compound of formula (11):-

where R4 is as defined with reference to formula (4) and Ra is C14 alkyl, benzyl or phenyl; thereafter where R4 is N-oxo-6-methyl-3-pyridyl; N-oxo-4,6-dimethyl-3-pyridyl; or N-oxo-5,6-dimethyl-3-pyridyl; converting the compound of formula (2) so obtained into the corresponding compound of formula (2) where R4 is 6-hydroxymethyl-3-pyridyl; 6-hydroxymethyl-4-methyl-3-pyridyl; or 6-hydroxymethyl-5methyl-3-pyridyl; and optionally converting the compound of formula (2) so obtained into a pharmaceutically acceptable salt.

10. A pharmaceutical compositions comprising a compound as claimed in any one of claims 1 to 9 and a pharmaceutically acceptable carrier.

11. A compound as claimed in any one of claims 1 to 9 for use as a histamine H1-antagonist.

12. A compound of formula (3):-

and salts thereof where R1, R2 and R3 are as defined with reference to formula (2) in claim 1.